Muscarinic acetylcholine receptor Inhibitors
8 drugsAbout Muscarinic acetylcholine receptor
The Muscarinic acetylcholine receptor is a key component of the parasympathetic nervous system, binding acetylcholine and influencing diverse physiological processes.
Muscarinic acetylcholine receptors are therapeutic targets with weak genetic support, including associations with insomnia (score 0.22) and corneal ulcers (score 0.19). Colocalization data shows 2 strong eQTL/pQTL signals (max H4: 0.97).
Eight FDA-approved small molecule drugs target this receptor, including GLYRX-PF, ISOPTO ATROPINE, and COBENFY. These drugs address conditions categorized as 'other' (7 drugs) and central nervous system disorders (1 drug).
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 81% attractiveness score.
- White space opportunity in Bladder Cancer with only 2 trials.
Muscarinic acetylcholine receptor Genetic Evidence
Genetic evidence offers weak support for the target, with a max score of 0.22.
Further research is needed to validate the target genetically before investing heavily.
Evidence Across Diseases
2 totalGWAS and other genetic studies link CHRM1 to 2 diseases.
🔗 Colocalization Evidence 2 strong
max H4: 0.97eQTL/pQTL signals for CHRM1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Muscarinic acetylcholine receptor Drugs
Eight companies have approved drugs, with NOVEL LABS INC, AZURITY, and AbbVie among the top players.
The presence of multiple companies suggests moderate competition and potential partnership opportunities.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| OXYTROL | AbbVie | 2003 | 2 |
| PREVDUO | AZURITY | 2023 | 2 |
| HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | PADAGIS US | 1983 | 1 |
| HYCODAN | GENUS | 1943 | 1 |
| COBENFY | Bristol-Myers Squibb | 2024 | 1 |
Muscarinic acetylcholine receptor Drug Modality Landscape
Modalities
Routes of Administration
Muscarinic acetylcholine receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage.
Muscarinic acetylcholine receptor Clinical Trials 224 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 40 | 28 | 4 | 8 | 88% |
| Phase 2 | 47 | 28 | 3 | 16 | 90% |
| Phase 3 | 58 | 35 | 3 | 20 | 92% |
| Phase 4 | 79 | 63 | 6 | 10 | 91% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Muscarinic acetylcholine receptor Drug Approval Timeline (1943 - 2024)
The first drug was approved in 1943, and the most recent was in 2024, spanning 82 years.
The continued approval of new drugs suggests sustained interest and potential for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 8 companies competing
- • Market share by company
Full Drug Portfolio
- • All 8 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 8-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 180 clinical trials targeting Muscarinic acetylcholine receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities